Option Care Health is the largest independent home and alternate-site infusion platform in the country, and the equity now turns on whether a chronic-therapy reset is finished or still leaking patients. After years of double-digit growth, the first half showed that a single branded-biologic transition can flatten the top line even while acute work keeps winning share. The April shock, when management raised the chronic inflammatory disease headwind and cut revenue guidance, is the event that still sets the multiple. The second-quarter rebound is real, but it is a sequential repair, not a return to the old growth rate.
The June quarter showed that the acute franchise can still outrun the market while the chronic book merely stops shrinking. Revenue reached just over fourteen hundred million, a low-single-digit gain against last year and a clearer step up from the first quarter. Adjusted earnings before interest, taxes, depreciation, and amortization, the cash-earnings proxy management uses, rose a bit faster than sales as selling costs came down. Acute therapies again grew in the high single digits. Chronic revenue was only flat year over year, and the company still embeds a six-hundred-basis-point revenue drag plus a fifty-five million gross-profit hole from the chronic inflammatory book. That is the tension: the print looks cleaner, but the headwind is still in the model.
Cash conversion and a large repurchase are doing more work for per-share earnings than volume is. Operating cash in the quarter was heavy, and the company bought back a hundred and fifty million of stock, nearly five percent of the shares then outstanding. The open question for the rest of the year is whether chronic census starts compounding again, or whether the market is correctly paying a mid-cycle services multiple for a platform that has become a cash-return story first and a growth story second.